Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
  • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
  • A01N43/06—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings
  • A01N43/12—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings condensed with a carbocyclic ring
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
  • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
  • A01N43/38—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
  • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
  • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
  • C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
  • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
  • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
  • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/54—Spiro-condensed
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins

Definitions

• the present invention relates to substituted 3- (biphenyl-1-yl) -8.S-di-fluoro-4-hydroxy-1-azaspiro [4.5] dec-3-en-2-ones of the formula (Ia) for therapeutic purposes, pharmaceutical compositions comprising the compounds according to the invention and their use in therapy, in particular for the prophylaxis and / or therapy of tumor diseases.
• Acetyl-CoA carboxylases play a key role in cellular fatty acid homeostasis.
• ACCs are biotin-containing enzymes that catalyze the carboxylation of acetyl-CoA to malonyl-CoA in an ATP-dependent manner (Kim, 1997, Harwood, 2005, Tong, 2005).
• This reaction which proceeds as two half reactions, a biotin carboxylase (BC) reaction and a carboxyl transferase (CT) reaction, is the first preliminary step in fatty acid biosynthesis and is the first
• ACCl and ACC2 Two human ACC isoforms are known, ACCl and ACC2, which are encoded by two different genes (LuTFI ABU-ELHEIGA et al., 1,995, Jane WIDMER, et al., 1,996).
• ACCl is expressed in lipogenic tissue (liver, adipose tissue), localized in the cytosol, and fills the malonyl-CoA pool, which serves as the C2 unit donor for the de novo synthesis of long-chain fatty acids by FASN and subsequent chain extension.
• ACC2 is predominantly expressed in oxidative tissues (liver, heart, skeletal muscle) (Bianchi et al., 1990, Kim, 1997), associated with the mitochondria, and regulates a second pool of malonyl-CoA. This controls the fatty acid oxidation by the inhibition of carnitine inmallyltransferase I, the enzyme which facilitates the entry of long-chain fatty acids into the mitochondria for ⁇ -oxidation (Milgraum LZ, et al., 1997, Widmer J. et al. 1996). Both enzymes show a very large sequence homology and are similarly regulated by a combination of
• ACC activity is strictly controlled by a number of dietary, hormonal, and other physiological mechanisms such as forward allosteric
• ACCl knockout mice are embryonic lethal (Swinnen, et al., 2006, Abu-Elheiga, et al., 2005). ACC2 knockout mice show reduced levels of maionyl-CoA in skeletal and cardiac muscle
• Fatty acid oxidation in muscle decreased liver fat levels, decreased levels of total body fat, increased levels of UCP3 in skeletal muscle (as a sign of increased energy expenditure), decreased body weight, decreased levels of plasma free fatty acids, decreased plasma glucose levels, decreased levels of glycogen im Tissues and are protected from diet-induced diabetes and obesity (Abu-Elheiga et al, 2001, 2003, Oh et al., 2005).
• upregulation of ACC and increased lipogenesis has been observed in many tumor cells (Swinnen, et al., 2004, Heemers, et al., 2000, Swinnen, et al. , 2002, Rossi, et al., 2003, Milgraum, et al., 1997, Yahagi, et al., 2005). This phenotype is very likely to contribute
• EP0454782 and US5759837 protect the use of fatty acid synthesis inhibitors to inhibit tumor cell growth. Cyclic ketoenols are not revealed.
• PCT Patent Application PCT / EP99 / 01787 published as WO 99/48869 corresponding to European Patent EP 1 066 258 B1, relates to novel arylphenyl-substituted cyclic ketoenols, a majority of the processes for their preparation and their use as pesticides and herbicides.
• EP-A-0 262 399 and GB-A-2 266 888 disclose similarly structured compounds (3-arylpyrrolidine-2,4-diones), of which no herbicides are disclosed. Insecticidal or acaricidal activity has become known. Known with herbicides. insecticidal or acaricidal action are unsubstituted, bicyclic 3-aryl-pyrrolidine-2,4-dione derivatives (EP-A-355 599, ⁇ - ⁇ -4 ⁇ 5 21 1 and JP-A-12-053 670) and substituted monocyclic 3-aryl-pyrrolidine-2,4-dione derivatives (EP-A-377 893 and ⁇ - ⁇ -442 077).
• EP-A-442 073 polycyclic 3-arylpyrrolidine-2,4-dione derivatives
• II I-arylpyrrolidine-dione derivatives EP-A-456 063, EP-A-521 334, EP-A No. 5,996,288, EP-A-613,884, EP-A-1 3 885, WO 95/01 971, WO 95/26 954, WO 95/20 572, ⁇ - ⁇ -0 668 267, WO 96/25 395, WHERE
• ketalsubstituted 1 -H-arylpyrrolidine-2,4-diones from WO 99/16748 and (spiro) - ketalsubstituted N-alkoxy-alkoxy-substituted aryl-pyrrolidindione from JP-A-14 205 984 and Ito M. et al. Bioscience, Biotechnology and Biochemistry 67, 1230-1238, (2003).
• WO 06/024411 discloses herbicidal compositions containing ketoenols.
• WO 2005/089118 and WO2007 / 039286 generically disclose nitrogen-containing bicyclic structures for therapy, 5'-biphenyl-substituted cyclic ketoenols not being specifically mentioned.
• the object of the present invention is to provide structures for the therapy of diseases.
• Tumors are suitable and have advantages over known in the art structures. Particularly interesting are compounds which have a selectivity against human ACC2, ie inhibit human ACC1 stronger than human ACC2.
• the main aim is to provide structures for the treatment of diseases that strongly inhibit human ACC1.
• the sought structures are said to inhibit human ACC1 more than human ACC2, i. have a selectivity against human ACC2.
• structures are to be provided for the therapy of diseases which additionally also possess one, more preferably several or even all of the following properties: they inhibit human ACC1 after single measurement or better on average from several measurements with an IC50 of less than 300 nM, better of less than 200 nM, more preferably less than 100 nM in the described assay, they inhibit human ACC2 after single measurement or better on average from several measurements with an IC50 of more than 0.5 ⁇ , better of more than 1.5 ⁇ , still better than 2 ⁇ in the described assay, the ratio of IC50 for the inhibition of human ACC2 to IC50 for the inhibition of human ACC1 after single measurement or better in the mean of several measurements is at least a factor of 8, better at least a factor of 15 better at least a factor of 20, they inhibit tumor cell proliferation of MCF7 cell lines after single measurement or better in the mean of several measurements with an IC 50 of less than 250 nM, better less than 100 nM, even better less than 50 nM in the described assay, they have
• Single measurement or better in the mean of several measurements in the described assay they have a protein binding constant at HSA of greater than 1 ⁇ / ⁇ after single measurement or better in the mean of several measurements in the described assay, they have a free fraction of more than 0.1%, more preferably more than 0.2%, of single measurements of human plasma protein binding, or better, on average, several measurements in the described assay, they have a ratio of free fractions with respect to mouse plasma protein and human Plasma protein by a factor of less than 15, better less than 10 after single measurement, or better in the mean of several measurements, they have a ratio of free fractions with respect to binding to the plasma protein of different species, resulting in an acceptable, estimated human dose pharmacokinetic parameters leading to an acceptable, estimated dose of fluman and allowing administration as a drug.
• the estimated daily human dose is less than 2 g, better under 1 g per patient.
• R la represents a methyl group or a chlorine atom
• R " represents a hydrogen atom or a methyl group
• R 3a represents a hydrogen or a fluorine atom
• R 4 "represents a chlorine or fluorine atom
• the compounds of formula (la) have surprisingly highlighted by a good enzyme inhibition of the human ACC's.
• the compounds of the invention have an increased selectivity against ACC2 and inhibit especially ACCl. This property was unpredictable and qualifies the compounds of the invention for reduced therapy
• Physiologically acceptable salts of the compounds according to the invention of the formula (Ia) also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium)
• Potassium salts alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, such as, for example and preferably ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclo- hexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine.
• alkaline earth salts for example calcium and magnesium salts
• ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, such as, for example and preferably ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine,
• compositions containing the compounds of the invention according to the formula (Ia) and at least one or more further active compounds, in particular for the prophylaxis and / or therapy of tumor diseases.
• the compounds according to the formula (Ia) according to the invention can act systemically and / or locally.
• it may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, o table or as an implant or stent.
• the compounds of the invention according to the formula (Ia) can be administered in suitable administration forms.
• Compounds of the invention according to the formula (Ia) in crystalline and / or amorphized and / or dissolved form such as tablets (uncoated or coated tablets, for example with enteric or delayed-dissolving or insoluble coatings which control the release of the compound of the invention), orally disintegrating tablets or films / wafers, films / lyophilisates in the oral cavity , Capsules (for example hard or
• Soft gelatin capsules Soft gelatin capsules
• dragees granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
• Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
• a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
• absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally.
• parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
• Inhalation medicines including powder inhalers, nebulizers
• nasal drops solutions, sprays; lingual, sublingual or buccal tablets to be applied, films / wafers or capsules, suppositories, ear or ophthalmic preparations, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (such as patches), milk, Pastes, foams, scattering powders, implants or stents.
• the compounds according to the invention of the formula (Ia) can be converted into the mentioned application forms. This can be done in a conventional manner by mixing with inert,
• Non-toxic, pharmaceutically suitable excipients happen. These adjuvants include, among others.
• Carriers e.g., microcrystalline cellulose, lactose, mannitol
• solvents e.g., liquid
• Polyethylene glycols Polyethylene glycols
• emulsifiers for example Natnumdodecylsulfat,
• binders e.g., polyvinylpyrrolidone
• synthetic and natural polymers e.g., albumin
• stabilizers e.g., antioxidants such as
• dyes e.g., inorganic pigments such as iron oxides
• dyes e.g., inorganic pigments such as iron oxides
• Flavor and / or odor remedies Flavor and / or odor remedies.
• auxiliaries may, for example, vehicles, fillers, disintegrants, binders, humectants, lubricants, adsorbents and agents, diluents, solvents, cosolvents, emulsifiers, solubilizers, flavoring agents, colorants, preservatives, stabilizers, wetting agents, salts for changing the osmotic pressure or buffers are used.
• the pharmaceutical formulations can be any suitable pharmaceutical formulations.
• auxiliaries for the purposes of the invention may be, for example, salts, saccharides (mono-, di-, tri-, oligo-, and / or polysaccharides), proteins, amino acids, peptides, fats, waxes, oils, hydrocarbons and derivatives thereof, the auxiliaries may be of natural origin or synthetically or partially synthetically obtained.
• the auxiliaries may be of natural origin or synthetically or partially synthetically obtained.
• the present invention relates to the compounds according to the invention of the formula (Ia).
• They can be used for the prophylaxis and treatment of human diseases, in particular tumors.
• the compounds of the invention according to the formula (Ia) can be used in particular to inhibit or reduce cell proliferation and / or cell division and / or to induce apoptosis.
• the compounds according to the invention of formula (Ia) are particularly suitable for the prophylaxis and / or treatment of hyper-proiiferative diseases such as
• BPH benign prostate hyperplasia
• tumors according to the invention for example, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast, tumors of the breast,
• Genitourinary tract eye, liver, skin, head and neck, thyroid, parathyroid gland, bone, connective tissue and metastases of these tumors.
• hematological tumors are treatable
• treatable as breast tumors are:
• tumors of the respiratory tract are treatable.
• tumors of the brain are treatable.
• Medullobl astome For example, as tumors of the male reproductive organs are treatable: prostate carcinomas,
• tumors of the female reproductive organs are treatable:
• tumors of the gastrointestinal tract are treatable:
• Tumors of the urogenital tract are, for example, treatable:
• tumors of the eye are treatable:
• tumors of the liver are treatable:
• tumors of the skin are treatable:
• tumors of the head and neck are treatable:
• sarcomas are treatable:
• lymphomas are treatable
• Treatable as leukemias for example:
• the compounds of the invention according to the formula (Ia) can be used for the prophylaxis and / or therapy of:
• Pancreatic Carcinoma Renal Cell Carcinoma, Hepatocellular Carcinoma, Malignant Melanoma and Other Skin Tumors, Non-Small Cell Lung Cancer, E nd metri u mk arzi no m.
• Colorectal carcinoma and prostate cancer are particularly advantageously for the prophylaxis and / or therapy of breast cancers, in particular hormone receptor-positive breast cancers, colorectal carcinomas, prostate carcinomas, in particular
• Another object of the present application are the compounds of the invention according to the formula (Ia) for use as medicaments, in particular for the prophylaxis and / or therapy of tumor diseases.
• Another object of the present application are the compounds of the invention according to the formula (Ia) for the prophylaxis and / or treatment of breast carcinoma, pancreatic carcinoma, renal cell carcinoma, hepatocellular carcinoma, malignant melanoma and other flaut tumors, non-small cell lung carcinoma, endometrial carcinoma, colorectal carcinoma or prostate cancer.
• Another object of the present application are the compounds of the invention according to the formula (Ia) for the prophylaxis and / or treatment of breast cancer, in particular
• Another object of the invention is the use of the compounds of the invention according to the formula (Ia) for the manufacture of a medicament.
• Another object of the present application is the use of the compounds of the invention according to the formula (Ia) for the manufacture of a medicament for the prophylaxis and / or therapy of tumor diseases.
• Another object of the present application is the use of the compounds of the invention according to the formula (Ia) for the preparation of a medicament for prophylaxis and / or
• Bronchial carcinoma, endometrial carcinoma, colorectal carcinoma or prostate cancer Bronchial carcinoma, endometrial carcinoma, colorectal carcinoma or prostate cancer.
• Another object of the present application is the use of the compounds of the invention according to the formula (Ia) for the production of a medicament for the prophylaxis and / or treatment of breast cancer, in particular hormone receptor-positive breast carcinomas, colorectal carcinomas, prostate cancer, especially androgen receptor negative
• Prostate carcinoma or non-small cell lung carcinoma are Prostate carcinoma or non-small cell lung carcinoma.
• Another object of the present application is the use of the compounds of the invention according to the formula (Ia) for the prophylaxis and / or therapy of tumor diseases.
• Another object of the present application is the use of the compounds of the invention according to the formula (Ia) for the prophylaxis and / or treatment of breast carcinoma, pancreatic carcinoma, renal cell carcinoma, hepatocellular carcinoma, malignant melanoma and other skin tumors, non-small cell lung carcinoma, endometrial carcinoma, colorectal carcinoma or prostate cancer.
• a further subject matter of the present application is the use of the compounds according to the invention of the formula (Ia) for the prophylaxis and / or therapy of breast cancers, in particular hormone receptor-positive breast carcinomas, colorectal carcinomas,
• Prostate carcinomas especially androgen receptor-negative prostate carcinomas or non-small cell bronchial carcinomas.
• Another object of the present application are pharmaceutical formulations in the form of tablets containing one of the compounds of the invention according to the formula (Ia) for the prophylaxis and / or treatment of breast carcinoma, pancreatic carcinoma, renal cell carcinoma, hepatocellular carcinoma, malignant melanoma and other skin tumors, non-small cells
• Bronchial carcinoma, endometrial carcinoma, colorectal carcinoma or prostate cancer Another object of the present application are pharmaceutical formulations in the form of tablets containing one of the compounds of the invention according to the formula (Ia) for the prophylaxis and / or treatment of breast cancer, especially hormone receptor-positive breast carcinomas, colorectal carcinomas, prostate cancer, especially androgen receptor negative prostate carcinoma or Non-small cell lung carcinomas.
• Another object of the invention is the use of the compounds of the invention according to the formula (Ia) for the treatment of diseases associated with proliferative processes.
• the compounds according to the invention of the formula (Ia) can be used alone or as required in
• Compound of the invention and one or more further active ingredients, in particular for the prophylaxis and / or therapy of the aforementioned diseases.
• the compounds of the invention according to the formula (Ia) can be combined with known anti-hyperproliferative, cytostatic or cytotoxic substances for the treatment of cancers.
• the combination of the compounds according to the invention with other substances commonly used for cancer therapy or also with radiotherapy is particularly indicated.
• suitable combination active ingredients are:
• Fosteabin Fotemustin, Fulvestrant, Gammagard, Gemcitabine, Gemtuzumab, Gleevec, Giiadel, Goserelin, Granisetron hydrochloride, Histrelin, Hycamtin, Hydrocorton, erythro- Hydroxynonyladenine, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, interferon-alpha, interferon-alpha-2, interferon-alpha-2a, interferon-alpha-2 ⁇ , interferon-alpha-nl, interferon-alpha-n3, interferon-beta, interferon -gamma- ⁇ , Interleukin-2, Introu A, Iressa, Irinotecan, Kytril, Lapatinib, Lentinan Sulfate, Letrozole, Leucovorin, Leuprolide, Leuprolide Acetate, Levamisole,
• Methotrexate Metvix, Miltefosine, Minocycline, Mitomycin C, Mitotan, Mitoxantrone, Modrenal, Myocet, Nedaplatin, Neulasta, Neumega, Neupogen, Nilutamide, Nolvadex, NSC-631570, OCT-43, Octreotide, Ondansetron hydrochloride, Orapred, Oxaliplatin, Paclitaxel , Pediapred, Pegaspargase, Pegasys, Pentostatin, Picibanil, Piloca in hydrochloride, Pirarubicin, Plicamycin, Porfimer Sodium,
• Tamoxifen Tamsulosin, Tasonermin, Tastolactone, Taxoter, Teceleukin, Temozolomide, Teniposide, Testosterone Propionate, Testred.
• Interferon gamma Interferon gamma, intron PEG, ixabepilone, keyhole limpet-1 lemocyanin.
• L-651582 lanreotide, lasofoxifene, libra, lonafamib, miproxifen, minodronate, MS-2 9, liposomal MTP-PE, MX-6, nafarelin, nemorubicin, neovastate, nolatrexed, oblimersen, onco-TCS, osmidem.
• the compounds according to the invention can be combined with anti-hyperproliferative agents, which can be given by way of example-without this enumeration being conclusive: Aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine, bleomycin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, 2 ', 2'-difluorodetoxycytidine, docetaxel, Doxorubicin (adriamycin), epirubicin, epothilone and its derivatives, erythro-hydroxynonyladenine, ethinyl estradiol, etoposide, fludarabine phosphate, 5-fluoro
• the compounds of the invention of formula (Ia) may also be combined with biological therapeutics such as antibodies (e.g., Avastin, Rituxan, Erbitux, Herceptin) and recombinant proteins.
• biological therapeutics such as antibodies (e.g., Avastin, Rituxan, Erbitux, Herceptin) and recombinant proteins.
• the compounds of the invention according to the formula (Ia) can also achieve positive effects in combination with other anti-angiogenic therapies, such as Avastin, axitinib, regorafenib, recentin. Sorafenib or sunitinib. Combinations with inhibitors of the
• Proteasomes and TORs as well as antihormones and steroidal metabolic enzyme inhibitors are particularly suitable because of their favorable side effect profile.
• the compounds of the formula (Ia) according to the invention can be prepared with the synthesis routes A and / or B.
• R 3a and R 4a have the abovementioned meanings
• a a -B (OH) 2, a boronic acid ester, preferably Boronklapinakolester, or BF 3 is T.
• the Suzuki couplings are generally carried out in inert solvents, in the presence of a catalyst, optionally in the presence of an additional reagent, preferably in a temperature range from room temperature to 130 ° C at atmospheric pressure.
• the reactions can also be carried out in a closed vessel with heating in the microwave.
• catalysts are conventional palladium catalysts for Suzuki reaction conditions, preferably catalysts such as e.g. Dichlorobis (triphenylphosphine) palladium,
• a ligand such as dicyclohexyl [2 ', 4', 6'-tri (propan-2-yl) biphenyl-2-yl] phosphine.
• Additional reagents are, for example, potassium or cesium acetate, cesium, potassium or sodium carbonate, potassium tert-butylate, cesium fluoride, potassium phosphate or sodium or potassium hydroxide.
• additional reagents such as cesium carbonate and / or aqueous sodium hydroxide solution
• inert solvents include ethers such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane, hydrocarbons such as benzene, xylene or toluene, or carboxylic acid amides such as dimethylformamide, dimethylacetamide or N-methylpyrrolidone, or Alkyl sulfoxides such as dimethyl sulfoxide, or mixtures of the solvents with alcohols such as methanol or ethanol and / or water, is preferably 1, 2-dimethoxyethane.
• the compound of formula (IIa) can be prepared by reacting the compounds of formula (IIa)
• B a is C 1 -C 6 -alkyl, preferably ethyl or methyl, is reacted under Dieckmann condensation conditions.
• the Dieckmann condensations are generally carried out in inert solvents in the presence of a base, preferably in a temperature range from room temperature to 130 ° C at atmospheric pressure.
• bases are alkali metal or alkaline earth metal alkoxides, such as sodium or potassium tert-butylate, sodium methoxide or ethanolate; potassium tert-butylate is preferred.
• Inert solvents are, for example, ethers, such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane, hydrocarbons, such as benzene, xylene or toluene, or carboxamides, such as dimethylformamide, dimethylacetamide or N-methylpyrrolidone, or alkyl sulfoxides, such as dimethyl sulfoxide, or alcohols, such as methanol or ethanol, dimethylformamide being preferred ,
• the compounds of the formula (IVa) can be prepared by reacting compounds of the formula (Va) or a salt of compounds of the formula (Va)
• reaction is generally carried out in inert solvents by reacting the compounds of the formula (Via) first with thionyl chloride or an equivalent reagent known to the expert and in the second stage with compounds of the formula (Va) or a salt of the compounds of the formula (Va) in Presence of a base such.
• B. triethylamine or potassium carbonate are reacted.
• inert solvents in the presence of a dehydrating reagent, optionally in the presence of a base, preferably in a temperature range of -30 ° C to 50 ° C at atmospheric pressure.
• Inert solvents are, for example, halogenated hydrocarbons, such as dichloromethane or trichloromethane, hydrocarbons, such as benzene or toluene, nitromethane, tetrahydrofuran, 1,4-dioxane, dimethylformamide or acetonitrile. It is likewise possible to use mixtures of the solvents.
• acetonitrile dichloromethane, dimethylformamide, tetrahydrofuran or toluene.
• bases are alkali metal carbonates such as sodium carbonate or potassium carbonate or bicarbonates or organic bases such as trialkylamines, for example triethylamine, N-methylmorpholine, ⁇ '-methyl- piperidine. 4-dimethylaminopyridine or diisopropylethylamine.
• Carbodiimides such as NN'-diethyl, NN, '-Dipropyl-, NN'-diisopropyl-, NN'-dicyclohexylcarbodiimide, N- (3-dimethylaminoisopropyl) -N'-ethylcarbodiimide hydrochloride (EDC) are suitable as dehydrating reagents in this case, for example.
• EDC N-dimethylaminoisopropyl
• N-cyclohexylcarbodiimide-N'-propyloxymethyl-polystyrene PS-carbodiimide
• carbonyl compounds such as carbonyldiimidazole
• 1,2-oxazolium compounds such as 2-ethyl-5-phenyl-I, 2-oxazolium-3-sulfate or 2-ter - Butyl-5-methyl-isoxazolium perchlorate
• acylamino compounds such as 2-ethoxy-1-ethoxycarbonyl-1, 2-dihydroquinoline, or propanephosphonic anhydride, or isobutyl chloroformate, or bis (2-oxo-3-oxazolidinyl) phosphoryl chloride , or O- (BenzotTiazol-l-yl) -A T, 7V, N ', A T' tetra-methyluroniumhexafluoiOphosphat (HBTU), 2- (2-oxo-l- (2H
• Benzotriazole-1-ylxytris (dimethylamino) phosphonium hexafluorophosphate (BOP), or benzotriazol-1-yloxytris (pyrrolidino) phosphonium hexafluorophosphate (PyBOP), or N-hydroxysuccinimide, or mixtures thereof, with bases,
• the condensation is carried out with PyBOP, TBTU or with EDC in the presence of HOBt.
• the compounds of the formula (Ia) according to the invention can be prepared by reacting a compound of the formula (VIIa)
• R la , R 2a , R '. R 4a and B a have the meanings given above, under the conditions given above in a Dieckmann condensation reaction.
• the compounds of the formula (VIIa) can be prepared by reacting compounds of the formula (Va) or a salt of compounds of the formula (Va) in which B has the abovementioned meaning, with compounds of the formula (VIIIa)
• R ia , R 2a , R 3a and R 4a have the meanings given above, under the abovementioned amide coupling conditions.
• the compounds of the formula (VIIIa) can be prepared by reacting the compounds of the formula (IVa) in which R 1a and R 2a have the meanings mentioned above in a Suzuki reaction under the abovementioned conditions with compounds of the formula (IIIa ), in
• the compounds of the formula (Va) required for synthesis route A and B or salts of compounds of the formula (Va) in which B a has the abovementioned meaning can be prepared by reacting the compound of the formula (FXa) or a salt of Compound of the formula (IXa)
• the compound of the formula (Xa) can be prepared by reacting the compound of the formula (XIa)
• V.l-b Table 1, line 3, p. 41 and Table 2, line 3, p.44 of WO08 / 06791 1
• V.2-h Example I-1-A 1 S of WO03 / 059065
• Table V shows the comparative examples, which Applicant regards as the closest prior art in the overview.
• the product was taken up in methylene chloride, extracted with 50 ml of 1N aqueous sodium hydroxide solution, the aqueous phase acidified with aqueous 1 N hydrochloric acid, filtered off with suction, washed with water, slurried with 25 ml of hot acetonitrile on the ultrasonic bath, filtered off with suction, washed and dried. 5.70 g (55% of theory) of the title compound were obtained.
• the purification was carried out by a P1 .CT identification on silica gel with hexane / ethyl acetate 1/1 as eluent. 0.7 g (70% of theory) of the title compound were obtained. Subsequently, 395 mg were again purified by HPLC [column: Chromatorex C18, 10 ⁇ m, 125 mm ⁇ 30 mm; Eluent: What s he / acetonitrile gradient with the addition of 0.1% formic acid]. 121 mg of the title compound were obtained.
• the enzyme activity is measured by quantifying the adenosine di-phosphate (ADP) formed as a by-product of the enzyme reactions using the ADP-Glo TM detection system from Promega.
• ADP adenosine di-phosphate
• ATP adenosine triphosphate
• ADP-GLO reagent an adenylate cyclase
• kinase detection reagent is then converted the formed ADP into ATP and converted this in a luciferase-based reaction into a Glow luminescence signal.
• a 100X concentrated solution of the test substance in DMSO were pipetted into a white low-volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2.5 ⁇ l of a solution of hACCI in assay buffer [50 mM HEPES / NaOH pH 7.5, 2mM MgCl 2 , 2mM potassium citrate, 12mL of Nal ICCk 2mM thio-threitol (DTT), 0.005% (w / v) bovine serum albumin (BSA)], and mix for 15 min min incubated to allow a Voritati the substances to the enzyme prior to the enzyme reaction.
• assay buffer 50 mM HEPES / NaOH pH 7.5, 2mM MgCl 2 , 2mM potassium citrate, 12mL of Nal ICCk 2mM thio-threitol (DTT), 0.005% (w / v) bovine serum albumin (BSA)
• concentration of hACC1 was adjusted to the respective activity of the enzyme and adjusted so that the assay worked in the linear range. Typical concentrations were in the range of 1.75 ng / ⁇ .
• test substance was incubated on the same microtiter plates at 10 different concentrations ranging from 20 to 10 nM (20 ⁇ , 6.7 ⁇ , 2.2 ⁇ , 0.74 ⁇ , 0.25 ⁇ , 82 ⁇ , 27 ⁇ , 9.2 ⁇ , 3.1 ⁇ M and 1 ⁇ M, respectively)
• Serial dilutions were assayed at the level of 10X concentrated solution prior to assay by serial 1: 3 dilutions) in duplicate values for each concentration and IC 50 values were calculated using a 4-parameter fit using in-house software.
• the hACC2 inhibitory activity of the substances of this invention was measured in the hACC2 assay described in the following paragraphs.
• the enzyme activity is measured by quantification of adenosine di-phosphate (ADP) as a by-product of the enzyme reactions using the ADP-Glo TM detection system from Finna Promega.
• ADP adenosine di-phosphate
• ATP adenosine triphosphate
• ADP-GLO reagent an adenylate cyclase
• kinase detection reagent is then converted the formed ADP into ATP and converted this in a luciferase-based reaction into a Glow luminescence signal.
• the enzyme used was recombinant C-terminal FLAG-tagged human ACC2 (acetyl-coenzyme A carboxylase 2, GenBank Accession No. NP 001084) (amino acids 27-end) expressed in baculovirus-infected insect cells (Hi5) and purified by anti-FLAG - Affinity chromatography.
• 50 ⁇ l of a 1 ⁇ 10 fold concentrated solution of the test substance in DMSO were pipetted into a white low-volume 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). 2.5 ⁇ of a solution of hACC2 in assay buffer [50 mM HEPES / NaOH pH 7.5.
• concentration of hACC2 was adjusted to the respective activity of the enzyme and adjusted so that the assay worked in the linear range. Typical concentrations were in the range of 2 ng / ⁇ .
• the reaction was stopped by adding 2.5 ⁇ of the "ADP-GLO reagent” (1: 1, diluted 5-fold) and the resulting mixture incubated for 1 h at 22 ° C to fully add the unreacted ATP into cAMP Subsequently, 2.5 ⁇ of the "Kinase Detection Reagent" (1.2 times more concentrated than indicated by the manufacturer) was added, the resulting mixture incubated for 1 h at 22 ° C and then the luminescence with a suitable instrument (Viewlux or Topcount from Perkin -Elmer or Pherastar from BMG Labtechnologies). The amount of light emitted was taken as a measure of the amount of ADP formed and thus of the enzyme activity of hACC2.
• test substance was incubated on the same microtiter plates at 10 different concentrations ranging from 20 ⁇ M to 1 nM (20 ⁇ , 6.7 ⁇ , 2.2 ⁇ , 0.74 ⁇ , 0.25 ⁇ , 82 ⁇ , 27 ⁇ , 9.2 ⁇ , 3.1 ⁇ M and 1 ⁇ M , the
• the substances were tested in cell-based assays, which means the ability of the substances to tumor cell proliferation after 96 hours
• the cell viability was tested by the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). The cells were at a density of 2000-5000 cells / well
• the ACC1 expression was determined by means of a microrray. The RNA was turned off for that
• RNA extraction reagent (Invitrogen) was used and purification was performed using the RNeasy Mini Kit (Qiagen).
• DNase I Qiagen digestion was performed to eliminate genomic DNA.
• total RNA analysis was performed using an RNA LabChip on an Agilent Bioanalzer 2100 Platform (Agilent Technologies) and RNA concentration determined using the Peqlab NanoDrop System.
• the "one-cycle eukaryotic target labeling assay" from Affymetrix was used and the array was subsequently read on an Affymetrix GeneChip 3000 scanner (Affymetrix)
• the partition coefficient octanol / water P or D is a key parameter for estimating membrane penetration and permeability. It is defined as the ratio of the equilibrium concentrations of a substance in the two-phase system octanol / water.
• c octanol concentration of the substance in the octanol phase
• the logP describes the distribution behavior of a substance that exists exclusively in its neutral form.
• the logD describes the distribution behavior of a substance at a certain pH value; Depending on the ionization constant pKa of the substance, part of the substance may be present in ionic form, part in neutral form.
• a formamide solution was used. For this purpose, 7 mg of formamide were dissolved in 10 ml of methanol. ⁇ of this stock solution were mixed with 500 ⁇ l methanol and 200 ⁇ l water.
• TRANSIL Intestinal Absorbance & HSA Binding Combined Assay Kit was used. This is a 96-well microtiter plate (96 well-MTP) filled with transil, with which the binding to MA-transil and HSA-transil can be determined for every eight active substances. For each active substance a row with 12 wells is available on the Transil plate. Two wells serve as a reference and are filled only with buffer pl I 7.4. Five more wells contain MA-Transil in varying increasing concentrations, the five remaining wells contain HSA-transil in varying increasing concentrations.
• HPLC-MS High Performance Liquid Chromatography-mass spectrometry
• the active ingredients were delivered in a 96 well MTP.
• This plate is called a mother plate.
• Per well 30 ⁇ 1 of a 10 mmol drug solution in DMSO (dimethyl sulfoxide) were included.
• Two wells at the beginning (well AI) and at the end of the plate (well 1 1 1) were filled with 30 ⁇ l of 10 mmol warfarin solution in DMSO.
• Warfarin whose membrane affinity and binding to HSA is known, serves to verify the accuracy of the measurement.
• a daughter plate was prepared with the dilution 1 to 4000 with a mixture buffer pH 7.4 and DMSO in the ratio 1 + 1.
• the active ingredient concentration per well was 2.5 ⁇ / liter, the volume per well was 400 ⁇ .
• the 96 active ingredients from the daughter plate were distributed over a total of 12 Transil plates. Per well of the daughter plate 12 times 20 ⁇ 1 were taken. The concentration per well in the transil plate was 0.25 ⁇ 1 / ⁇ , corresponding to a dilution of 1 to 10. The content of DMSO was 5%.
• the filled transil plates were each resuspended for two minutes, then allowed to stand for at least two minutes at room temperature and then centrifuged at 600 rpm for five minutes. Subsequently, 20 ⁇ supernatant from each well of the transil plate was removed from the pipetting robot and transferred to a separate microtiter plate. In each case, the supernatants of four transil plates were combined in a microtiter plate ("pooled"), so that at the end there were three pooled microtiter plates each with 80 ⁇ l of solution and an active substance concentration of 62.5 nM per well.
• the pipetting robot made a dilution of 1 to 10 000 000 in an acetonitrile-water mixture in the ratio 8 + 2 in a separate microtiter plate from the mother plate.
• This microtiter plate was measured with the Discovery Quant Optimize software from AB Sciex on the HPLC-MS.
• the three pooled microtiter plates were measured on the HPLC-MS using the software Discovery Quant Analyze from AB Sciex.
• Determination of the binding of test substances to plasma proteins is carried out by equilibrium dialysis using the Ht-dialysis apparatus (96well) made of Teflon and a semipermeable membrane (regenerated cellulose, MW CO 12-14K). This separates 150 ⁇ each of a plasma and a buffer side (50 M phosphate buffer). The test substance is added to the plasma side in 2 concentrations (usually 3 and 0.3 ⁇ ) and binds to plasma proteins. The unbound portion of the test substance passes through the membrane and spreads on both sides until an equilibrium is established (approximately after 6-8h at 37 ° C). The substance concentration on buffer and plasma side determined by LC-MS analysis.
• both sides are brought to dilution with buffer or plasma on the same matrix (10% plasma) and then precipitated with methanol. From the quotient of the buffer and plasma concentration, the free (unbound) fraction (fu) is calculated. Controls include stability samples and recovery samples.
• the substance is dialyzed in buffer against buffer to check the non-specific binding to the apparatus and membrane and the adjustment of the equilibrium. Since dilution of the plasma occurs during incubation due to the osmotic pressure of the plasma proteins (volume shift), this possible error is determined by weighing empty plasma samples and included in the calculation of the fu. Balance and plasma stability should not be less than 80% and recovery at least 30%. A free fraction of ⁇ 1% is called high, between 1 and 10% as moderate and> 10% as low plasma protein binding. 3.6 Pharmacokinetic parameters
• test substances were applied in dissolved form for both intravenous and intragastric administration, using compatible solubilizers such as PEG400 and / or ethanol in a tolerated amount.
• test substances were applied at a dose of 0.1 - 1 mg / kg.
• the application was in the male rat as a bolus injection, in the female dog as an infusion (15 min). At various times after bolus injection or before and after the 15-minute infusion about 100-150 ⁇ were.
• Blood samples were taken from the jugular vein (rat) or from the saphenous vein (dog) via a catheter. The blood samples were treated with lithium I leparin as an anticoagulant and kept refrigerated until further processing. After centrifuging the samples for 15 min at 3000 rpm, an aliquot of ⁇ was taken from the supernatant (plasma) and precipitated by addition of 400 ⁇ _, cold ACN or methanol (absolute).
• the precipitated samples were frozen overnight at 20 ° C, then centrifuged again at 3000 rpm for 15 min before removing 15 ⁇ L of the clear supernatant for concentration determination.
• the analysis was carried out by an Agilent 1200 HPLC system with connected LCMS / MS detection.
• test substances were administered intragastrally as a bolus to fasting male rats or female dogs at a dose of 0.3-1 mg / kg by means of a probe.
• approximately 100-150 ⁇ L blood samples were taken from a jugular vein catheter (rat) or from the saphenous vein (dog).
• the blood samples were treated with lithium-1 leparin as an anticoagulant and kept refrigerated until further processing (refrigerator). After centrifuging the samples for 15 min at 3000 rpm, an aliquot of ⁇ , the supernatant (plasma) was taken and by addition of 400 ⁇ . cold ACN or methanol (absolute) like.
• the precipitated samples were frozen overnight at -20 ° C, then centrifuged for 15 min at 3000 rpm, before 150 ⁇ , of the clear supernatant was removed for concentration determination.
• the analysis was carried out by an Agilent 1200 HPLC system with connected LCMS / MS detection
• AUCnorm Area under the plasma concentration time profile from time zero to infinity extrapolated divided by the body weight normalized dose (in kg * L / h); AUC (0-tn) norm: integrated area under the plasma concentration time profile from time zero to the last time a plasma concentration was measurable, divided by the body weight normalized dose (in kg * L / h); Cmax: maximum concentration of test chemical in plasma (in ⁇ g L); Cmax, norm: maximum concentration of test chemical in plasma divided by body weight normalized dose (in kg / L); tl / 2: half-life within a specified interval (here: terminal tl / 2, in h); Fobs%: observed oral bioavailability, AUC (0-tn) norm after i.g. Gabe divided by AUC (0-tn) norm to i.v. Administration, tmax: Time at which the maximum concentration of the test substance in the plasma is also measured.
• the AUC (0-tn) norm is divided after administration of a microcrystalline substance suspension by the AUC (0-tn) norm after administration of a substance solution. 3.7. in vivo VVirksanikeit
• Xeeograft models were used in immunosuppressed mice to determine the antitumoral efficacy in the living organism.
• the maximum tolerable dose (MTD) was determined according to the following protocol:
• mice Female nude mice (NMRI-nude (nu / nu) mice, Taconic M & B A / S) received daily orally a defined dose of the test substance over a period of 3 weeks and were daily compared
• the highest administered dose was defined as the MTD, during which no animal died during the treatment phase and there was no more than 10% decrease in body weight compared to baseline.
• xenograft models were then used in which the test substances were added to their MTD or, if this had not previously been determined, at the highest formulation that can be formulated in the standard vehicle and, in some cases, also at lower dosages.
• a prostate carcinoma model with hormone-independent human PC-3 cells in male nude mice NMRI-nude (nu / nu) mice, Taconic M & B A / S) was used primarily.
• 3 million tumor cells (suspended in medium + Matrigei) 1: 1, final 0.1 ml) were injected subcutaneously into the flank per animal. When the tumors reached 20-30 mm 2 tumor area, the mice were placed in the
• the T / t value calculated by the effect on the final tumor weight was calculated: mean of the tumor weights in the treatment group divided by the average of the tumor weights in the vehicle group. 4.
• Enzyme assays together. For accurate determination of selectivity, measurements of inhibition of ACCl and ACC2 (IC50 determinations) were compared in pairs using copies of the same series of dilutions in both assays. If either the ACCl or the ACC2-IC50 determination was not evaluated due to poor data quality, both measurements were ignored and were not listed in the table. The selectivity of the inhibition of ACCl versus the inhibition of ACC2 was then determined as the average of the selectivities observed in the individual measurements.
• ACCl expression in tumor and normal tissue was determined by means of a microarray (FIG. 1). The expression of ACCl was significantly upregulated compared to
• Pancreatic carcinomas 4.4 Octanol-water partition coefficients (logP / D), membrane affinity (logMA) and protein binding to human serum albumin (K d HSA)
• Table 4 shows the determined logP / D, logMA and K lä I ISA values.
• the evaluation of the HPLC peaks was carried out via Discovery Quant Analyze.
• the calculation of the results (logMA or binding constant at HSA K ⁇ j) took place via an Excelworkbook provided by Sovicell. Table 4
• Plasma Protein Deposition by Equilibrium Dialysis Table 5 shows the binding determined by glial weight analysis to human, mouse, and rat plasma proteins.
• Table 6 shows the pharmacokinetic parameters from the rat.
• Example 1 - 1 was administered to female nude mice (NMRI nu / nu):
• the MTD is above 100 mg / kg for a daily regimen of 21 days daily.
• the prediction of the human pharmacokinetic (PK) parameters was based on the in vivo PK parameters, which were collected for the rat (single species scaling), taking into account species differences in the free fraction (fu) in the plasma.
• the effective area-of-area (AUC) was determined based on the measured plasma concentration-time profile for in vivo efficacy in the mouse PC3 tumor model (nu / nu mouse).
• the present invention also relates to novel halogen-substituted spirocyclic etoenols of the formula (I), to a plurality of processes for their preparation and to their use as pesticides and / or herbicides and / or fungicides.
• the invention also provides selective herbicidal compositions which contain halogen-substituted spirocyclic ketoenols on the one hand and a crop plant compatibility-improving compound on the other hand.
• the present invention further relates to the enhancement of the action of crop protection agents containing in particular halogen-substituted spirocyclic ketoenols, by the addition of ammonium or phosphonium salts and, optionally, penetration promoters, the corresponding agents, processes for their preparation and their use in crop protection as insecticides and / or acaricides and / or or nematicides and / or fungicides and / or for the prevention of undesired plant growth.
• EP-A-0 262 399 and GB-A-2 266 888 disclose similarly structured compounds (3-aryl-pyrrolidine-2,4-diones), of which no herbicides are disclosed. Insecticidal or acaricidal activity has become known. Unsubstituted, bicyclic 3-arylpyrrolidine-2,4-dione derivatives are known having herbicidal, insecticidal or acaricidal activity (EP-A-355 599, EP-A-415 21 1 and JP-A-12-053 670) and substituted monocyclic 3-arylpyrrolidine-2,4-dione derivatives (EP-A-377 893, EP-A-442 077 and WO 10/066780).
• EP-A-442 073 polycyclic 3-arylpyrrolidine-2,4-dione derivatives
• EP-A-456 063 EP-A-521 334, A-596,298, EP-A-613,884, ⁇ - ⁇ -613,885, WO 95/01,971, WO 95/26954, WO 95/20 572, EP-A-0 668 267, WO 96/25395 , WO 96/35 664, WO 97/01 535, WO 97/02 243, WO 97/36 868, WO 97/43275, WO 98/05638, WO 98/06721, WO 98/25928, WO 99/24437, WO 99/43649, WO 99/48869, WO 99/55673, WO 01/17972, WO 01/23354, WO 01/74770, WO 03/013249, WO 03/06224
• ketalsubstituted 1-H-arylpyrrolidine-2,4-diones from WO 99/16748 and (spiro) - ketal-substituted N-alkoxy-alkoxy-substituted arylpyrrolidinediones are known from JP-A-14 205 984 and Ito M. et al., Bioscience, Biotechnology and Biochemistry 67, 1230-1238, (2003).
• the addition of safeners to etoenols is also known in principle from WO 03/013249.
• WO 06/024411 discloses herbicidal compositions containing ketoenols. With pharmaceutical effect are so far known WO 2011/098433, DE-A-102010008642, DE-A-102010008643 and DE -Number 102010008640.
• 3-aryl- ⁇ 3 -dihydrofuran on derivatives having herbicidal, acaricidal and insecticidal properties are known from: EP-A-528 156, EP-A-647 637, WO 95/26 954, WO 96/20 196, WO 96/25 395, WO 96/35 664, WO 97/01 535, WO 97/02 243, WO 97/36 868, WO 98/05 638, WO 98/06 721, WO 99/16748, WO 98 / 25 928, WO 99/43 649, WO 99/48 869, WO 99/55 673, WO 01/23354, WO 01/74 770, WO 01/17972, WO 04/024 688, WO 04/080 962, WO 04/111 042, WO 05/092 897, WO 06/000355, WO 06/029 799, WO 07/048545,
• W is hydrogen, halogen, alkyl, alkenyl, alkynyl, optionally substituted cycloalkyl, alkoxy, alkenyloxy, haloalkyl, haloalkoxy or cyano,
• X is halogen, alkyl, alkenyl, alkynyl, optionally substituted cycloalkyl, alkoxy, alkenyloxy, alkylthio, alkylsulfmyl, alkylsulfonyl, haloalkyl, haloalkoxy, haloalkenyloxy, nitro or cyano
• Y and Z are independently hydrogen, alkyl, alkenyl, alkynyl, optionally substituted
• A is halogen
• B represents halogen or a bond to the adjacent carbon atom, with the proviso that A and B are in the 3 and / or 4 ' position, D is Ni I or oxygen,
• G is hydrogen (a) or one of the groups stands in which
• E is a metal ion or an ammonium ion
• L is oxygen or sulfur
• M is oxygen or sulfur
• R l is in each case optionally halogen- or cyano-substituted alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl or polyalkoxyalkyl or in each case optionally by halogen, alkyl or alkoxy-substituted cycloalkyl or heterocyclyl or is in each case optionally substituted phenyl, phenylalkyl, hetaryl, phenoxyalkyl or hetaryloxyalkyl
• R 2 is in each case optionally halogen- or cyano-substituted alkyl, alkenyl, alkoxyalkyl or polyalkoxyalkyl or in each case optionally substituted cycloalkyl, phenyl or
• R 4 and independently of one another are each optionally halogen-substituted alkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alkenylthio or cycloalkylthio or in each case optionally substituted phenyl, benzyl, phenoxy or phenylthio,
• R 6 and R independently of one another represent hydrogen, in each case optionally halogen or cyano-substituted alkyl, cycloalkyl, alkenyl, alkoxy, alkoxyalkyl, in each case optionally substituted phenyl or benzyl, or together with the N atom to which they are bonded , form an optionally oxygen or sulfur containing and optionally substituted cycle.
• the compounds of the formula (I) can also be present in different compositions as optical isomers or mixtures of isomers, which can optionally be separated in a customary manner. Both the pure isomers and the mixtures of isomers, their preparation and use and agents containing them are the subject of the present invention. In the following, however, for the sake of simplicity, reference is always made to compounds of the formula (I), although both the pure compounds and, if appropriate, mixtures with different proportions of isomeric compounds are meant.
• A, B, E, L, M, W, XY Z, RR 2 , R ⁇ R 4 , R 5 , R 6 and R 7 have the meanings given above. Including the different meanings (a), (b), (c), (d), (e), (f) and (g) of the group G, the following main structures ( ⁇ -2-a) to ( ⁇ -2-g), when D is oxygen,
• A, B, E, L, M, W, X. Y, Z, R 1 . R 2 , R 3 , R 4 . R 5 , R 6 and R 7 have the abovementioned meaning.
• A, B, W, X, Y and Z have the meanings given above. if
• A, B. W, X, Y and Z have the meanings given above, and
• R 8 represents alkyl (preferably C ⁇ -C 6 alkyl), are condensed intramolecularly in the presence of a diluent and in the presence of a base.
• A, B, W, X, Y, Z and the meanings given above have intramolecularly condensed in the presence of a diluent and in the presence of a base.
• Hal is halogen (in particular chlorine or bromine) or ⁇ ) with carboxylic acids of anhydride of the formula (V)
• R ' has the meaning given above, if appropriate in the presence of a diluent and if appropriate in the presence of an acid binder;
• R and M have the meanings given above, if appropriate in the presence of a diluent and if appropriate in the presence of an acid binder;
• M and R ⁇ have the abovementioned meanings, if appropriate in the presence of a diluent and if appropriate in the presence of an acid binder,
• R ' has the abovementioned meaning, if appropriate in the presence of a diluent and if appropriate in the presence of an acid binder,
• Hal is halogen (in particular chlorine or bromine), if appropriate in the presence of a diluent and if appropriate in the presence of an acid binder,
• Me is a mono- or divalent metal (preferably an alkali metal or alkaline earth metal such as lithium, Sodium, potassium, magnesium or calcium), t for the number 1 or 2 and
• R '- independently of one another are hydrogen or alkyl (preferably C 1 -C 6 -alkyl), if appropriate in the presence of a diluent,
• A, B, D, W, X, Y and Z have the meanings given above, when compounds of the above-shown formulas (IIa -a) or (1-2a) in which A, B, D , W, X, Y and Z have the meanings given above, respectively
• R6 and L have the meanings given above, if appropriate in the presence of a diluent and if appropriate in the presence of a catalyst or reacted with carbamoyl chlorides or thio carb amides of chlorides of the formula (XIII)
• L, R 1 and R 2 have the abovementioned meanings, if appropriate in the presence of a diluent and if appropriate in the presence of an acid binder,
• X, Y and Z have the abovementioned meaning, is obtained when compounds of the formulas ( ⁇ - ⁇ ) or (1-2 '), in which A, B, D, G, W, X and Y are the abovementioned Have meaning and Z 'is preferably bromine or iodine and that compounds of the formulas (II) or (1-2) shown above, in which A, B, D, G, W, X, Y and Z have the abovementioned meaning, are obtained if compounds of the formulas ( II ") or (1-2"), in which A, B, D, G, W, X and Z have the abovementioned meaning and Y 'is preferably bromine or iodine
• OH OH or its esters in the presence of a solvent, in the presence of a catalyst (eg Pd complexes) and in the presence of a base (e.g., sodium carbonate, potassium phosphate),
• a catalyst eg Pd complexes
• a base e.g., sodium carbonate, potassium phosphate
• halogenated alcohols eg trifluoroethanol of the formula (XV)
• pesticides preferably as insecticides, acaricides, nematicides, fungicides and herbicides, moreover, in particular against crops, are very good plant tolerability and / or have favorable toxicological and / or environmental properties.
• certain substituted, cyclic ketoenols when used in conjunction with the compounds (safeners / antidotes) which improve the properties of Kulnirplan / ene, prevent the damage to the cultivated plants very well and are particularly advantageous as broadly effective combination preparations for the selective Control of undesirable plants in crops, such as in corn but also corn, soy and rice can be used.
• the invention also relates to selective herbicidal compositions containing an effective content of an active substance combination comprising as components at least one compound of the formula (I) in which A, B, D, G, W, X, Y and Z have the abovementioned meaning and
• the safeners are preferably selected from the group consisting of:
• n A is a natural number from 0 to 5, preferably 0 to 3;
• R A 1 is halo, (C 1 -C 4 ) alkyl, (CC 4 ) alkoxy, nitro or (C 1 -C 4 ) haloalkyl;
• W A is an unsubstituted or substituted divalent heterocyclic radical selected from the group consisting of partially unsaturated or aromatic five-membered heterocycles having 1 to 3 hetero ring atoms from the group N and O, at least one N atom and at most one O atom being present in the ring, preferably a radical from the group (W A 1 ) to (W A 4 ),
• R A 2 is OR A 3 , SR A 3 or NR A ' R A 4 or a saturated or unsaturated 3- to 7-membered heterocycle having at least one N atom and up to 3 heteroatoms, preferably from the group O and S, which is connected via the N-atom to the carbonyl group in (SI) and is unsubstituted or substituted by radicals from the group (Ci-C 4) alkyl, (CC) alkoxy or optionally substituted phenyl, preferably a radical of the formula oR a 3 , NHR A 4 or N (CH 3 ) 2 , in particular of the forms! OR A 3 ;
• R A 3 is hydrogen or an unsubstituted or substituted aliphatic
• Hydrocarbon radical preferably with a total of 1 to 18 ( " atoms;
• R A 4 is hydrogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy or substituted or unsubstituted phenyl;
• R 5 is A I I. (C 1 -C 8) alkyl, (C, -C 8) haloalkyl, (C, -C 4) alkoxy (d-C8) alkyl, cyano or COOR A9 wherein R A 9 is hydrogen, (CC 8) alkyl, (Ci-C 8) haloalkyl, (C, -C 4) alkoxy- (C, -C 4) alkyl, (Ci-C 6) Hydroxyaikyl, (C 3 -C 12) Cycloalkyl or tri (C 1 -C 4 ) alkylsilyl;
• R A 6 , R A 7 , R A 8 are the same or different hydrogen, (CC 8 ) alkyl, (CC 8 ) haloalkyl, (C 3 - C ! 2 ) cycloalkyl or substituted or unsubstituted phenyl; preferably: a) compounds of the Dicblorphenylpyrazolin-3-carboxylic acid type (Sl a ), preferably compounds such as 1- (2,4-dichloro-phenyl) -5-ethoxycarbonyl) -5-methyl-2-pyrazoline-3-carboxylic acid, 1- (2 , 4-Dichloo-phenyl) -5-ethoxycarbonyl) -5-methyl-2-pyrazoline-3-carboxylic acid ethyl ester (Sl-1) ("mefenpyr-diethyl”), and related compounds as described in WO-A-91 / 07874; b) Derivatives of dichlorophenylpyrazole
• B 1 is halogen, (CC 4 ) alkyl, (CC 4 ) alkoxy, nitro or (C, -C 4 ) haloalkyl;
• n B is a natural number from 0 to 5, preferably 0 to 3;
• R H " is OR B 3 , SR b 3 or NR B 3 R B 4 or a saturated or unsaturated 3- to 7-membered heterocycle having at least one N atom and up to 3 heteroatoms, preferably from the group O and S, which is connected via the N atom with the carbonyl group in (S2) and unsubstituted or substituted by radicals from the group (Ci-C 4 ) alkyl, (Ci-C) alkoxy or optionally substituted phenyl, preferably a radical of the formula OR B 3 , NHR B 4 or N (CH 3 ) 2 , in particular of the formula OR B 3 ;
• R B 3 is hydrogen or an unsubstituted or substituted aliphatic
• Hydrocarbon radical preferably with a total of 1 to 18 C atoms
• R B 4 is hydrogen, (C] -C 6 ) alkyl, (C 1 -C 6 ) alkoxy or substituted or unsubstituted
• TB is a (Ci or C 2) -alkanediyl chain which is carbonyl unsubstituted or substituted with one or two (Ci- C4) alkyl radicals or by [(dC 3) alkoxy]; preferably: a) Compounds of the 8-quinolinoxyacetic acid (S2 A), preferably (5-chloro-8- chinoiinoxy) acetic acid, ethyl (l -methylhexyl) ester ( "Cl oquint oc et-mexyl '') (S2-1) , (5-chloro-8-quinolinoxy) acetic acid (1, 3 -dimethyl-1-butyryl) ester
• Rc 1 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 2 -C 4 ) alkenyl, (C 2 -C 4 ) haloalkenyl,
• Rc 2 , Rc 3 are identical or different hydrogen, (Ci-C) alkyl, (C 2 -C 4 ) alkenyl, (C 2 -C 4 ) alkynyl, (C, -C 4 ) haloalkyl, (C 2 -C 4) haloalkenyl, (C, -C 4) alkylcarbamoyl (C 1 -C 4) alkyl, (C 2 - C 4) Alkenylcarbamoyl- (CC 4) alkyl, (Ci-C 4) alkoxy (CC 4) alkyl , Dioxolanyl- (C 1 -C 4) alkyl, thiazolyl, furyl, furylalkyl, thienyl, piperidyl, substituted or unsubstituted phenyl, or R c 2 and R c 3 together form a substituted or unsubstituted heterocyclic ring, preferably an o
• R-29148 (3-dichloroacetyl-2,2,5-trimethyl-1,3-oxazolidine) from Stauffer (S3-2), "R-28725" (3-dichloroacetyl-2,2, -dimethyl- 1,3-oxazolidine) from Stauffer (S3-3), "Benoxacor” (4-dichloroacetyl-3,4-dihydro-3-methyl-2H-1,4-benzoxazine) (S3-4), "PPG- 1292 "(N-allyl-N - [(1,3-dioxolan-2-yl) -methyl] -dichloroacetamide) from PPG
• AD-67 or "MON 4660” (3-dichloroacetyl-1-oxa-3-aza-spiro [4,5] decane) from Nitrokemia or Monsanto (S3-7),
• TI-35 (1-dichloroacetyl-azepane) from TRI-Chemical RT (S3-8),
• RD 2 is halogen, (C, -C 4) haloalkyl, (Ci-C 4) haloalkoxy, nitro, (Ci-C 4) alkyl, (dC 4) alkoxy, (C i -C) alkylsulfonyl, (CC 4) Alkoxycarbonyl or (Ci-C) alkylcarbonyl;
• RD 3 is hydrogen, (C 1 -C 4 ) alkyl, (C 2 -C 4 ) alkenyl or (C 2 -C 4 ) alkynyl;
• RD 4 is halogen, nitro, (CC 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (dC 4 ) haloalkoxy, (C 3 -C 6 ) cycloalkyl, phenyl, (C 1 -C 4 ) alkoxy, cyano, (C 1 -C 4 ) alkylthio, (C 1 -C 4 ) alkylsulfinyl, (C 1 -C 4 ) alkylsulfonyl, (C 1 -C 4 ) alkoxycarbonyl or (C 1 -C 4 ) alkylcarbonyl;
• RD 5 is hydrogen, (C 1 -C 6 ) alkyl, (C 3 -C 6 ) cycloalkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 5 -C 6 ) cycloalkenyl, phenyl or 3 to 6-membered heterocyclyl containing v D heteroatoms from the group of nitrogen, oxygen and sulfur, where the seven latter radicals are represented by v D substituents from the group halogen, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, ( C 1 -C 2) Alkylsulfmyl, (Ci-C 2) Alkylsuifonyl, (C 3 -C 6) Cycloaikyi, (C, - C 4) alkoxycarbonyl, (C i -C 4) alkylC arb ony 1, and phenyl and in the case
• R n is hydrogen, (CC 6 ) alkyl, (C 2 -C 6 ) alkenyl or (C 2 -C 6 ) alkynyl, where the three latter radicals are represented by v D radicals from the group halogen, hydroxy, (Ci-C 4 ) alkyl, (Ci-C 4 ) alkoxy and (Ci-C 4 ) alkylthio are substituted, or
• R D and R 6 together with the nitrogen atom carrying them a pyrrolidinyl or
• R D 7 is hydrogen, (Ci-C 4 ) alkylamino, di- (Ci-C 4 ) alkylamino, (Ci-C 6 ) alkyl, (C 3 -C 6 ) cycloalkyl, where the 2 last-mentioned radicals by v D substituents from the group halogen, (C] -C) alkoxy, (Ci-C 6 ) haloalkoxy and (Ci-C) alkylthio and in the case of cyclic radicals are also (Ci-C 4 ) alkyl and (Ci-C 4 ) haloalkyl substituted ; n D is 0, 1 or 2; m D is 1 or 2; v D is 0, 1, 2 or 3; preferred are compounds of the type of N-acylsulfonamides, for example the following formula (S4 a ), the z. B. are known from WO-A-97/45016 wherein
• Rn (Cj-C 6 ) alkyl, (C 3 -C 6 ) cycloalkyl, where the 2 latter radicals by v D substituents selected from the group consisting of halogen, (C] -C) alkoxy, (Ci-C 6 ) haloalkoxy and (Ci C 4 ) alkylthio and in the case of cyclic radicals also (C 1 -C 4 ) alkyl and (C 1 -C 4 ) haloalkyl;
• R D 4 is halogen, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, CF 3; m D 1 or 2; is 0, 1, 2 or 3; such as Acylsulfamoylbenzoeklareamide, for example, the following formula (S4 b ), for example, are known from WO-A-99/16744,
• R D 8 and R n '' are independently hydrogen, (DC 8) alkyl, (C 3 -C 8) Cycioaikyl, (C 3 - C 6) alkenyl, (C 3 -C 6) alkynyl,
• R D 4 is halogen, (C 1 -C 4 ) alkyl, (CC 4 ) alkoxy, CF 3 m D 1 or 2; for example, 1- [4- (N-2-methoxybenzoylsulfamoyl) phenyl] -3-methylurea, l- [4- (N-2-Methoxybenzoylsulfamoyl) phenyl] -3,3-dimethylurea,
• Carboxylic acid derivatives (S5) e.g.
• Ethyl 3,4,5-triacetoxybenzoate 3,5-dimethoxy-4-hydroxybenzoic acid, 3,5-dihydroxybenzoic acid, 4-hydroxysalicylic acid, 4-fluorosalicyclic acid, 2-hydroxycinnamic acid, 1, 2-dihydro-2-oxo-6- trifluoromethylpyridine-3-carboxamide, 2,4-dichlorocinnamic acid, as described in WO-A-2004/084631, WO-A-2005/015994, WO-A-2005/016001.
• R E 1 , R are independently halogen, (Ci-C 4 ) alkyl, (dC 4 ) alkoxy, (Ci-C 4 ) haloalkyl, (Ci-C 4 ) alkylamino, di- (CC 4 ) alkylamino, nitro;
• a E is COOR E 3 or COSR E 4
• 4 are independently hydrogen, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 4 ) alkynyl, cyanoalkyl, (C 1 -C 4 ) haloalkyl, phenyl, nitrophenyl, benzyl, halobenzyl, pyridinylalkyl and alkylammonium .
• ⁇ 1 is 0 or 1
• n E 2 , n E 3 are independently 0, 1 or 2, preferably:
• Methyl diphenylmethoxyacetate (CAS No. 41858-19-9) (S7-1).
• R F 2 is hydrogen or (C, -C 4 ) alkyl
• Ri ' is hydrogen, (Ci-C 8 ) alkyl, (C 2 -C) alkenyl, (C 2 -C) alkynyl, or aryl, wherein each of the aforementioned C-containing radicals unsubstituted or by one or more, preferably up to three identical or different radicals from the group consisting of halogen and alkoxy is substituted, or their salts, preferably compounds wherein
• X [CH, n F is an integer from 0 to 2, IV halogen, (C, -C 4) alkyl, (C, -C 4) haloalkyl, (C, -C 4) alkoxy, (C, -C 4) haloalkoxy,
• R F 2 is hydrogen or (dC 4 ) alkyl
• FV is hydrogen, (Ci-Cg) alkyl, (C 2 -C) alkenyl, (C 2 -C) alkynyl, or aryl, wherein each of the aforementioned C-containing radicals unsubstituted or by one or more, preferably up to three, same or various radicals from the group consisting of halogen and alkoxy substituted, mean, or their salts.
• S9 Agents from the class of 3- (5-tetrazolylcarbonyl) -2-quinolones (S9), e.g. 1,2-dihydro-4-hydroxy-1-ethyl-3- (5-tetrazolylcarbonyl) -2-quinolone (CAS No. 219479-18-2), 1,2-dihydro-4-hydroxy-1 -methyl-3- (5-tetanyazolylcarbonyl) -2-quinolone (CAS No. 95855-00-8), as described in WO-A-1999/000020.
• S9 1,2-dihydro-4-hydroxy-1-ethyl-3- (5-tetrazolylcarbonyl) -2-quinolone (CAS No. 219479-18-2), 1,2-dihydro-4-hydroxy-1 -methyl-3- (5-tetanyazolylcarbonyl) -2-quinolone (CAS No. 95855-00-8), as described in WO-A-1999/000020.
• RG 2 (C 1 -C 16 ) alkyl, (C 2 -C 6 ) alkenyl, (C 3 -C 6 ) cycloalkyl, aryl; Benzyl, halobenzyl, RG 3 is hydrogen or (Ci-C 6 ) alkyl.
• Si l active ingredients of the type of oxyimino compounds (Si l), which are known as seed dressing, such as.
• seed dressing such as.
• oxabetrinil ((Z) -l, 3-dioxolanylmethoxyimino (phenyl) acetonitrile)
• Cyometrinil or “CGA-43089” ((Z) -cyanomethoxyimino (phenyl) acetonitrile) (Sl 1 -3), which is known as a seed dressing safener for millet against damage by metolachlor.
• Naphthalene anhydride (1,8-naphthalenedicarboxylic anhydride) (S13-1), which is known as a seed safener for maize against thiocarbamate herbicide damage,
• MG 191 (CAS No. 96420-72-3) (2-dichloromethyl-2-methyl-1,3-dioxolane) (S13-5) from Nitrokemia, which is known as a safener for corn,
• Active substances which, in addition to having a herbicidal action against harmful plants, also have safener action on cultivated plants such as rice, such as, for example, rice.
• cultivated plants such as rice, such as, for example, rice.
• MY-93 S-1-methyl-1-phenylethyl-piperidine-1-carbothioate
• R ' represents a (C] -C6) haloalkyl, and RH' is hydrogen or halogen and
• R H 3 , R '' independently of one another are hydrogen, (C 1 -C 16 ) -alkyl, (C 2 -C 6 ) -alkenyl or (C 2 -C 6 ) -alkynyl, where each of the last-mentioned 3 radicals is unsubstituted or denotes one or more radicals the group halogen, hydroxy, cyano, (Ci-C 4 ) alkoxy, (C i -C 4 ) haloalkoxy, (Ci-C 4 ) alkylthio, (Ci-C 4 ) aikylamino, di [(Ci-C 4 ) aikyl ] -amino, [(dC 4 ) alkoxy] carbonyl, [(CC 4 ) haloalkoxy] carbonyl, (C 3 -C 6 ) cycloalkyl which is unsubstituted or substituted, phenyl which is un
• R is H 3 (dd) -alkoxy, (dd) alkenyloxy, (dd) alkynyloxy or (C 2 -d) haloalkoxy and R H 4 is hydrogen or (dd) -alkyl or
• RH 'and R H 4 together with the directly attached N atom, a four- to eight-membered heterocyclic ring, which may contain in addition to the N-atom and other hetero ring, preferably up to two further hetero ring N and O group and the is unsubstituted or substituted by one or more radicals from the group halogen, cyano, nitro, (d- C4) alkyl, (dd) haloalkyl, (dd) alkoxy, (C, -C 4) haloalkoxy and (dd) alkylthio, means.
• W is preferably hydrogen, halogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl C3-C6-cycloalkyl optionally substituted once or twice by C 1 -C 2 -alkyl, C 1 -C 2 -alkoxy, fluorine, chlorine, trifluoromethyl or C 3 -C 9 -cycloalkyl, C 1 -C 6 -alkoxy, C 4 -C 4 -haloalkyl, ci Crhaloalkoxy or cyano,
• X is preferably halogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, optionally mono- to disubstituted by C 1 -C 2 -alkyl, C 1 -C 2 -alkoxy, fluorine, chlorine, trifluoromethyl or C 3 -C 4 -alkyl.
• Y and Z are each, independently of one another, hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 9 -alkenyl, C 2 -C -alkynyl, optionally mono- or disubstituted by C 1 -C 2 -alkyl, C 1 - ( 2 -
• V 1 is preferably hydrogen, halogen, Cj-C ⁇ alkyl, Ci-Cg alkoxy, Cj-CSS alkylthio, CJ-Cg-alkylsulphinyl, C ⁇ -CG alkylsulfonyl, C i -C 4 haloalkyl, C
• A is preferably halogen
• B is preferably halogen or a bond which is bonded to the same carbon atom as A, with the proviso that A and B are in the 3 ' and / or 4 ' position,
• D is preferably NH or oxygen
• G is preferably hydrogen (a) or one of the groups
• E is a metal ion or an ammonium ion
• L is oxygen or sulfur and M is oxygen or sulfur
• R ' preferably represents in each case optionally halogen or cyano-substituted C 1 - (2 () _
• R ⁇ is preferably each optionally substituted by halogen or cyano
• R ' preferably represents optionally halogen-substituted Cj-C 8 -alkyl or in each case optionally halogen, C] -Cg-alkyl, Cj -Cg-alkoxy, C 1 -C 4 -I lalogenalkyl. C 1 -C 4 haloalkoxy, cyano or nitro substituted phenyl or benzyl,
• R4 and R ⁇ are, independently of one another preferably represent in each case optionally halogen-substituted Cj-C8 alkyl, Cj-C 8 alkoxy, Cj -C 8 alkylamino, di- (C ⁇ -C 8 alkyl) amino, C] C 8 -alkylthio or C 3 -C 8 -alkenylthio or in each case optionally by halogen, nitro, cyano, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy, C 1 -C 4 -alkylthio, C 1 -C 4 -haloalkylthio, Cj ⁇ alkyl or C
• R ⁇ and R ⁇ are, independently of one another preferably represent hydrogen, represent in each case optionally substituted by halogen or cyano, Ci-C8 alkyl, C3-C 8 -Cycioalkyl, C1 -C8 alkoxy, C3-C 8 - alkenyl or C ⁇ -C 8 -alkoxy-C 2 -C 8 -alkyl, door in each case optionally substituted by halogen, C] -C 8 - alkyl, C
• halogen is fluorine, chlorine, bromine and iodine. especially for fluorine, chlorine and bromine.
• W is particularly preferably hydrogen, chlorine, bromine.
• X is particularly preferably chlorine, bromine. iodine, C 1 -C -alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl, C 3 -C -cycloalkyl optionally substituted by methyl, ethyl, methoxy, fluorine, chlorine, trifluoromethyl or cyclopropyl, C 1 -C 4 -alkoxy,] -C4-I lalogena! Ky !. C1-C4-haloalkoxy or cyano,
• Y and Z are particularly preferably each independently hydrogen, fluorine, chlorine, bromine, iodine, Cj-C4-alkyl, ⁇ -alkene], C 2 -C 4 -alkynyl, optionally simply by methyl, ethyl, methoxy, fluorine, chlorine, trifluoromethyl or cyclopropyl-substituted C3-C6-cycloalkyl, Cj-Cg-alkoxy, C
• one of the radicals Y or Z may be (Het) -aryl, particularly preferably represents hydrogen, fluorine, chlorine, bromine, Cj -Cg-alkyl, j -C ⁇ alkoxy, C " i - " 2 "haloalkyl, C 1 - ( " 2- "haloalkoxy, nitro, cyano or optionally monosubstituted to fluoro, chloro, bromo, C 1 -C 6 -alkyl, C 1 -C 4 -alkoxy, C j -C 2 -Haloalkyl, C 1 -C 4 -halogenoalkoxy, nitro or cyano-substituted phenyl, and more preferably independently of one another are hydrogen, fluorine, chlorine, bromine, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C j - (I lalogenalkyl
• B is particularly preferably fluorine, chlorine or a bond which is bonded to the same carbon atom as A, with the proviso that A and B are in the 3 'and / or 4' position
• D is particularly preferably NH or Oxygen
• G is particularly preferably hydrogen (a) or one of the groups
• E is a metal ion or an ammonium ion
• L is oxygen or sulfur
• M is oxygen or sulfur
• R ' particularly preferably represents in each case optionally monosubstituted to trisubstituted by fluorine or chlorine -C] 6- alkyl, C 2 -C 16 -alkenyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, C 1 -C 8 -alkylthio, C 1 -C 4 -alkyl or poly-C 1 -CG- alkoxy-C] -C4-alkyl or optionally once or twice by fluorine, chlorine, C] -C5-alkyl or C
• -C4 -alkyl in each case optionally mono- to disubstituted by fluorine, chlorine, bromine or C] -C4-alkyl pyrazolyl, thiazolyl, pyridyl, pyrimidyl, furanyl or thienyl, represents optionally mono- to disubstituted by fluorine, chlorine, bromine or C] -C4 alkyl-substituted phenoxy-C
• R ⁇ particularly preferably represents in each case optionally mono- to trisubstituted by fluorine or chlorine, C j -C j g alkyl, C 2 -C 16 alkenyl, C j -C 6 -alkoxy-C 2 -C 6 -alkyl or poly -C-C 6 - alkoxy-C2-Cg-alkyl, which is optionally monosubstituted to disubstituted j by fluorine, chlorine, C1 -C4 -alkyl or C -C4 -alkoxy-substituted C3-C7-cycloalkyl or represents in each case optionally mono- to trisubstituted by Fluorine, chlorine, bromine, cyano, nitro, C
• R ' particularly preferably represents optionally mono- to trisubstituted by fluorine or chlorine-substituted Cj-Cg-alkyl or in each case optionally mono- to disubstituted by fluorine, chlorine, bromine, Cj-C4-alkyl, Ci-C4-alkoxy, C -C2 -haloalkoxy , ] -C 2-! lalogenalkyl. Cyano or nitro substituted phenyl or Be / yl.
• R 1 and R 2 independently of one another particularly preferably represent hydrogen, in each case optionally mono- to trisubstituted by fluorine or chlorine, C 1 -C -alkyl, C 2 -C -cycloalkyl, C 1 -C 6 -alkoxy, C 3 -C 6 -alkenyl or C j - C6-alkoxy-C2-Cg-alkyl, in each case optionally monosubstituted to trisubstituted by fluorine, chlorine, bromine, C 1 -C 5 -alkyl) cycloalkyl.
• halogen is fluorine, chlorine and bromine, in particular fluorine and chlorine.
• W is very particularly preferably hydrogen, chlorine, bromine, methyl, ethyl, vinyl, ethynyl, propynyl, cyclopropyl, methoxy, ethoxy or trifluoromethyl,
• X is very particularly preferably chlorine, bromine, methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, propynyl, cyclopropyl, methoxy, ethoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy or cyano
• Y and Z are very particularly preferably each independently Hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, vinyl, ethynyl, propynyl, cyclopropyl, methoxy, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, cyano or a phenyl radical,
• V is very particularly preferably hydrogen, fluorine or chlorine
• V 2 very particularly preferably represents hydrogen, fluorine, chlorine, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy or trifluoromethyl,
• A is most preferably fluorine
• B very particularly preferably represents fluorine or a bond which is bonded to the same carbon atom as A,
• D is most preferably NU or oxygen, is very particularly preferably hydrogen (a) or one of the groups
• E is a metal ion or an ammonium ion
• L is oxygen or sulfur
• M is oxygen or sulfur
• R very particularly preferably represents in each case optionally monosubstituted to trisubstituted by fluorine or chlorine, C 1 -C 10 -alkyl, C 2 -C 10 -alkenyl, C 1 -C 4 -alkoxy-C 1 -C 2 -alkyl, C 1 -C 4 Alkylthio-C 1 -C 2 -alkyl or C 3 -C 9 -cycloalkyl which is optionally monosubstituted by fluorine, chlorine, methyl, ethyl or methoxy, optionally once or twice by fluorine, chlorine, bromine, cyano, nitro, methyl, ethyl, n-propyl, i-propyl, methoxy, ethoxy, trifluoromethyl or trifluoromethoxy-substituted phenyl, each optionally optionally substituted by chlorine, bromine or methyl furanyl, thienyl or pyridy
• X particularly preferably represents chlorine, bromine, methyl, ethyl, methoxy or ethoxy (highlighted for chlorine, methyl or ethyl),
• Y and Z are particularly preferably independently of one another hydrogen, chlorine, bromine, methyl, trifluoroethoxy or the radical
• V 1 is particularly preferably fluorine or chlorine
• V 2 particularly preferably represents hydrogen, fluorine or chlorine (highlighted for hydrogen, likewise highlighted for fluorine),
• Z stands for hydrogen, bromine, A particularly preferably represents fluorine,
• B is particularly preferably fluorine or a bond, where A and B are bonded to the same carbon atom in the 4 'position,
• D is especially preferred for N! 1 or oxygen
• G is particularly preferably hydrogen (a) or one of the groups
• E is a metal ion or an ammonium ion
• R ' is particularly preferably Cj-C] Q-alkyl, J - ( " 4-alkoxy-, -CS-alk vi, C3-C6-cycloalkyl, for optionally simply by chlorine substituted phenyl or for thienyl, (highlighted for Ci-Cio-alkyl),
• R- is particularly preferably C 1 -C 4 -alkyl, C 2 -C 1 2-alkenyl or benzyl, (for C 1 -C 4 -alkyl).
• Saturated or unsaturated hydrocarbon radicals such as alkyl, alkanediyl or alkenyl can also be used in
• optionally substituted radicals may be monosubstituted or polysubstituted, with multiple substituents the substituents being the same or different.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Zoology (AREA)
• Environmental Sciences (AREA)
• Agronomy & Crop Science (AREA)
• Pest Control & Pesticides (AREA)
• Plant Pathology (AREA)
• Dentistry (AREA)
• Wood Science & Technology (AREA)
• Epidemiology (AREA)
• Communicable Diseases (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oncology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Indole Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Furan Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (6)

Applications Claiming Priority (6)

Publications (1)

Family

ID=46671961

Family Applications (2)

Family Applications After (1)

Country Status (7)

Cited By (1)

Families Citing this family (22)

Citations (201)

Family Cites Families (12)

• 2012
  • 2012-02-14 WO PCT/EP2012/052520 patent/WO2012110518A1/de not_active Ceased
  • 2012-02-14 WO PCT/EP2012/052521 patent/WO2012110519A1/de not_active Ceased
  • 2012-02-14 CN CN201280018951.0A patent/CN103649049B/zh not_active Expired - Fee Related
  • 2012-02-14 CA CA2827398A patent/CA2827398A1/en not_active Abandoned
  • 2012-02-14 JP JP2013553914A patent/JP5905908B2/ja active Active
  • 2012-02-14 BR BR112013021021A patent/BR112013021021A2/pt not_active Application Discontinuation
  • 2012-02-14 CN CN201280018567.0A patent/CN103492367B/zh not_active Expired - Fee Related
  • 2012-02-14 JP JP2013553913A patent/JP2014508752A/ja active Pending
  • 2012-02-14 EP EP12703559.0A patent/EP2675789A1/de not_active Withdrawn
  • 2012-02-14 US US14/000,147 patent/US8946124B2/en not_active Expired - Fee Related
  • 2012-02-14 EP EP12703558.2A patent/EP2675788A1/de not_active Withdrawn
  • 2012-02-14 US US13/985,940 patent/US9000026B2/en not_active Expired - Fee Related

Patent Citations (211)

Non-Patent Citations (46)

Also Published As

Similar Documents

Legal Events